Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy

Shari Pilon-Thomas1, Krithika N. Kodumudi1, Asmaa E. El-Kenawi2,3, Shonagh Russell2, Amy M. Weber1, Kimberly Luddy2, Mehdi Damaghi2, Jonathan W. Wojtkowiak2, James J. Mule1, Arig Ibrahim-Hashim3, and Robert J. Gillies2

Abstract
Cancer immunotherapies, such as immune checkpoint blockade or adoptive T-cell transfer, can lead to durable responses in the clinic, but response rates remain low due to undefined suppression mechanisms. Solid tumors are characterized by a highly acidic microenvironment that might blunt the effectiveness of antitumor immunity. In this study, we directly investigated the effects of tumor acidity on the amplitude and quality of T-cell activation in response to antigen activation of the T-cell receptor (TCR) is tightly controlled by the engagement of inhibitory receptors, such as PD-1, Lag-3, Tim-3, BTLA, and CTLA4. The ability of tumors to coopt these inhibitory pathways plays an important role in the inhibition of T-cell responses within the tumor microenvironment (1, 2). Treatment with fully humanized neutralizing mAbs against CTLA4, PD-1, or its ligand PD-L1 has led to durable antitumor responses where conventional therapies have failed (3–5). However, response rates remain low, from 18% to 27% for anti-PD-1 antibodies (6) and 11% for anti-CTLA4 antibodies (7). Recent studies have shown that multiple checkpoints can be coexpressed on individual tumor (8–10). Indeed, a recent clinical trial combined PD-1 and CTLA4 blockade in patients with melanoma and showed an increase rate of objective tumor responses as compared with blocking either checkpoint alone, 40% versus 20% (11). However, there remain a significant proportion of nonresponders, suggesting that additional immunosuppressive pathways are active.

Introduction
The amplitude and quality of T-cell activation in response to antigen activation of the T-cell receptor (TCR) is tightly controlled by the engagement of inhibitory receptors, such as PD-1, Lag-3, Tim-3, BTLA, and CTLA4. The ability of tumors to coopt these inhibitory pathways plays an important role in the inhibition of T-cell responses within the tumor microenvironment (1, 2). Treatment with fully humanized neutralizing mAbs against CTLA4, PD-1, or its ligand PD-L1 has led to durable antitumor responses where conventional therapies have failed (3–5). However, response rates remain low, from 18% to 27% for anti-PD-1 antibodies (6) and 11% for anti-CTLA4 antibodies (7). Recent studies have shown that multiple checkpoints can be coexpressed on individual tumor-infiltrating lymphocytes, such as PD-1 “TIM-3” T cells, which are defective in proliferation and cytokine production (8–10). Indeed, a recent clinical trial combined PD-1 and CTLA4 blockade in patients with melanoma and showed an increase rate of objective tumor responses as compared with blocking either checkpoint alone, 40% versus 20% (11). However, there remain a significant proportion of nonresponders, suggesting that additional immunosuppressive pathways are active.

Regulatory T cells (Treg) or myeloid-derived suppressor cells (MDSC) are also known to blunt T-cell responses (12, 13). Tregs suppress antigen-specific T-cell response, and the removal of Tregs in murine models led to enhanced antitumor T-cell responses and tumor rejection (14). MDSCs are comprised of immature macrophages, granulocytes, and dendritic cells (DC; ref. 15). They suppress T-cell responses, reduce antigen-specific CD8+ T-cell proliferation, and increase T-cell death by apoptosis (16), and their elimination has been shown to enhance antitumor immunity and tumor regression in murine tumor models (17). In addition to these cell-based inhibitors of immune function, there are also secreted factors that block T-cell activation. The most widely studied of these are the kynurenines, which are synthesized by the tryptophan-metabolizing enzyme, indoleamine-2,3-dioxygenase (IDO). IDO can be expressed by cancer cells and is normally expressed by DCs in response to IFNγ to blunt immune activation (18). There has also been evidence that tumor-derived acidity also plays a role in immunosuppression (19).

Solid tumors are unequivocally acidic (20). This is commonly believed to be a consequence of high rates of fermentative metabolism in a poorly perfused environment (21). However, newer models point to an active role for the membrane-bound carbonic anhydrase IX (CAIX) in establishing extracellular acidity (22). This is relevant, as CAIX is an independent negative prognostic indicator in a number of cancers, including, inter alia, breast (23), lung (24), and ovarian cancers (25).
Tumor acidity is important to tumor progression, as it has been shown to promote local invasion and metastasis (26), and metastasis can be inhibited by neutralization of acidity with oral buffers (27, 28). Tumor-derived acidity is also hypothesized to suppress immune function (19). For example, lactic acidosis is a strong negative prognostic indicator in sepsis (29). In vitro, acidic pH (6.5) can suppress T-cell functions, including IL2 secretion and the activation of T-cell receptors (30), although the mechanism by which this occurs is not known. Likewise, there is evidence that acid pH affects other components of the immune system, such as DCs, MDSCs, or macrophages, yet these effects are also not known with certainty (19). For example, inhibition of proton pumps on tumor cells with omeprazole can hamper tumor-induced suppression of macrophages in vitro and in vivo (31, 32), yet this activity may be due to off-target effects, as the target for these drugs are not known to be expressed in the immune system. It may be assumed that the effects of acidity are not mediated via acidification of the intracellular pH (pHi), as the pHi has been shown to be highly buffered in activated T cells (33). More recently, families of specific acid-sensing receptors have been identified (34) and shown to transduce extracellular acidity into intracellular signals. For example, acid pH has been shown to activate the G-protein, T-cell inhibitory receptor, T-cell death–associated gene-8 (TDAG8; ref. 35), and this has been shown to be responsible for a reduction in c-myc translation in lymphocytes (36). In this study, we examined the effect of tumor acidity on antitumor immunotherapeutic strategies and observed that the neutralization of tumor pH with bicarbonate increased response to checkpoint inhibitors and, importantly, led to cures in combination with adoptive T-cell therapy.

Materials and Methods

Mice
Female C57BL/6 mice (6–8 weeks old) were purchased from Harlan Laboratories. TDAG8 knockout (TDAG8 KO) mice on the C57BL/6 background were purchased from The Jackson Laboratory. Pmel, OT-I, and OT-II mice were bred and housed at the Animal Research Facility of the H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL). Mice were humanely euthanized if a solitary subcutaneous tumor exceeded 1.5 cm in diameter, appeared necrotic, or interfered with locomotion. Tumors were collected and weighed.

Cell lines and culture
B16 melanoma (obtained from ATCC), Yumm 1.1 melanoma (kindly provided by Marcus Rosenberg, Yale University, New Haven, CT), and Panc02 pancreatic cancer (a kind gift from Emmanuel Zervos, East Carolina University, Greenville, NC) cell lines were cultured in complete media (CM): RPMI media supplemented with 10% heat-inactivated FBS, 0.1 mmol/L nonessential amino acids, 1 mmol/L sodium pyruvate, 2 mmol/L fresh l-glutamine, 100 mg/mL streptomycin, 100 U/mL penicillin, 50 mg/mL gentamicin, 0.5 mg/mL fungizone (all from Life Technologies), and 0.05 mmol/L 2-ME (Sigma-Aldrich). The cell lines tested negative for mycoplasma contamination. All cell lines were passaged less than 10 times after initial revival from frozen stocks. All cell lines were validated in core facilities prior to use.

In vitro T-cell culture
T cells were isolated from the spleens of pmel, OT-I, or OT-II mice using T-cell columns (R&D Systems). Pmel T cells were cultured for 2 days in CM, containing 10 IU/mL IL2 and 5 pg/mL gp10025-33 peptide. T cells were collected and cultured in CM, pH 6.6 or 7.4, with gp10025-33 peptide (10 mcg/mL) for 24 hours. Freshly isolated OT-1 T cells were cultured in CM, pH 6.6 or 7.4, with OVAASIINFEKL peptide (10 mcg/mL) for 24 hours. Freshly isolated OT-II T cells were cultured in CM, pH 6.6 or 7.4, with OVA123-339 peptide (10 mcg/mL) for 24 hours. Freshly isolated T cell from TDAG8 KO and wild-type (WT) littermates were cultured with 5 mcg/mL plate-bound anti-CD3 antibodies for 48 hours. For restimulation experiments, pmel T cells were collected after 24 hours of culture in CM, pH 6.6 or pH 7.4, containing 10 mcg/mL gp10025-33 peptide and recultured in CM, pH 7.4, with 10 mcg/mL gp10025-33 peptide for 24 to 48 hours. Cell supernatants were collected and IFNγ production was measured by ELISA. For measurement of IFNγ production by flow cytometry, brefeldin A (1 mcg/mL) was added to the cell culture 4 hours prior to harvest. Cells were harvested and stained with live/dead Aqua (Invitrogen) to exclude dead cells. Surface staining was done with anti-mouse CD8 APC antibody, followed by intracellular staining with anti-mouse IFNγ PE, and data were acquired on the LSR II and analyzed using FlowJo software.

Treatment model
C57BL/6 mice received 200 mmol/L of sodium bicarbonate water 3 days prior to tumor injection and continued to receive bicarbonate water until the end of the experiment. Control mice received regular tap water. A total of 1 × 106 B16, Yumm 1.1, or Panc02 tumor cells were injected subcutaneously in the left flank of C57BL/6 mice. Mice received intraperitoneal injections of 20 mg/kg of anti-PD1 or anti-CTLA4 antibodies on day 3 and continued to receive antibodies every 3 to 4 days until the end of the experiment. Mice were humanely euthanized when tumors exceeded 1.5 cm in diameter, appeared necrotic, or interfered with locomotion. Tumors were collected and weighed.

Adaptive T-cell therapy
C57BL/6 mice received 200 mmol/L of sodium bicarbonate water 3 days prior to tumor injection and continued to receive bicarbonate water until the end of the experiment. Control mice received regular tap water. A total of 1 × 106 B16 tumor cells were injected subcutaneously in the left flank of C57BL/6 mice. Three days later, mice received a sublethal dose (600 cGy) of total body irradiation (TBI) administered by an X-ray irradiator. For adoptive transfer experiments, T cells were isolated from the spleens of pmel mice and cultured in media containing 10 IU/mL of IL2 and 5 mcg/mL of gp10025-33 in vitro for 5 days. On day 4 following tumor injection, 5 × 106 T cells were intravenously injected. IL2 (2.5εS IU) was given intraperitoneally following T-cell injection, continuing every 12 hours for 3 days, for a total of 6 injections. Following this treatment, tumor size was measured and recorded every 2 days.
Intracellular pH measurement

Pmel T cells were cultured at pH 7.4 in the presence of gp10025-33 peptide for 24 hours. Cells were washed and resuspended in serum-free media and SNARF-1, acetoxyethyl ester, acetate (Life Technologies) was added to a final concentration of 0.5 μmol/L. After 30-minute incubation, cells were split into two aliquots that were washed two times with PBS at either pH 6.6 or 7.4. In the last wash, each of the two aliquots were again split into two aliquots at each pH and resuspended in either regular PBS at pH 7.4 or high-K PBS containing 1 mg/mL collagenase, 0.1 mg/mL DNAse I, and 2.5 U/mL of hyaluronidase (all from Sigma-Aldrich), with constant stirring for 2 hours at room temperature. The resulting suspension was passed through a 70-μm cell strainer and washed once with HBSS. Cells were resuspended in PBS + 3% BSA to a concentration of 0.5–1 × 10^6 cells/mL for flow cytometric analysis. After red blood cell lysis with ACK lysis buffer, cells were stained in FACS buffer with the following antibodies for flow cytometric analysis: CD3, CD4, and CD8 for T-cell detection and CD11b, Ly6G, and Ly6C for MDSC detection (all from BD Biosciences). Live/Dead fixable near-IR or aqua fluorescent reactive dyes (Invitrogen) were used to exclude dead cells before analysis. Cells were acquired by LSR II equipped with four lasers (BD Biosciences), and the data were analyzed with FlowJo (Tree Star).

Flow cytometry

Spleens and tumors were harvested under sterile conditions. Single-cell suspensions were prepared, and red blood cells were removed using ACK lysis buffer. Tumor cell suspensions were prepared from solid tumors by enzymatic digestion in Hank’s Balanced Salt Solution (HBSS) (Life Technologies), containing 1 mg/mL collagenase, 0.1 mg/mL DNAse I, and 2.5 U/mL of hyaluronidase (all from Sigma-Aldrich), with constant stirring for 2 hours at room temperature. The resulting suspension was passed through a 70-μm cell strainer and washed once with HBSS. Cells were resuspended in HBSS and SNARF-1, acetoxymethyl ester, acetate (Life Technologies) was used to exclude dead cells before analysis. Cells were acquired by LSR II equipped with four lasers (BD Biosciences), and the data were analyzed with FlowJo (Tree Star).

Intracellular pH measurement

Pmel T cells were cultured at pH 7.4 in the presence of gp10025-33 peptide for 24 hours. Cells were washed and resuspended in serum-free media and SNARF-1, acetoxyethyl ester, acetate (Life Technologies) was added to a final concentration of 0.5 μmol/L. After 30-minute incubation, cells were split into two aliquots that were washed two times with PBS at either pH 6.6 or 7.4. In the last wash, each of the two aliquots were again split into two aliquots at each pH and resuspended in either regular PBS at the respective pH or high-K PBS containing 1 mg/mL nigericin at the respective pH. Samples were then analyzed by flow cytometry with laser excitation of approximately 543 nm and emissions at 530 and 680 nm. Ratios of fluorescence emission intensities of SNARF-1 at 580 and 640 nm, which are sensitive to pH, were then plotted.

qRT-PCR

RNA was extracted using RNeasy Isolation Kit (Qiagen). qRT-PCR was then carried out using iTaq Universal SYBR Green One-Step Kit (Bio-Rad) using the primer sequence (Table 1). Results were normalized using 36B4, then expressed as fold change (FC) \( = \frac{2^{-\Delta \Delta C_t}}{2^{-\Delta C_t}} \), where \( \Delta C_t = (C_{T-Tar} - C_{36B4})_{assay} - (C_{T-Tar} - C_{36B4})_{control} \) (37).

Table 1. Primers and sequences

<table>
<thead>
<tr>
<th>Primers</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>36B4 Forward</td>
<td>5'-CCGATCTGACACACACACT -3'</td>
</tr>
<tr>
<td>36B4 Reverse</td>
<td>5'-TCCACGCAATGAGTACAAAC-3'</td>
</tr>
<tr>
<td>IFNγ Forward</td>
<td>5'-CGTTATGTTGTTGATGTTG-3'</td>
</tr>
<tr>
<td>IFNγ Reverse</td>
<td>5'-CACACTGACATTGTCCTTG-3'</td>
</tr>
</tbody>
</table>
gp10025-33 peptide. These T cells were cultured with gp10025-33 peptide for 48 hours, and then further incubated with gp10025-33 peptide at acidic (6.6) or alkaline (7.4) pH for an additional 24 or 48 hours. As shown in Fig. 1A, there was no significant difference in the cell viability under acidic, compared with alkaline, conditions. However, at the same time, we observed a decrease in cell-associated IFN γ (Fig. 1B). In subsequent studies, we observed that the secretion of this cytokine was completely abolished in T cells cultured under acidic conditions (Fig. 1C). The effects of acidic pH were not due to irreversible effects on CD8+ signaling, as T cells, exposed to pH 6.6 for 24 hours and then shifted to pH 7.4 for 24 hours, regained the ability to secrete high levels of IFN γ (Fig. 1D). Identical results were observed when CD8+ T cells isolated from OT-1 mice, which transgenically express a TCR specific for the ovalbumin peptide (OVA323-339), were activated with OVA323-339 peptide at low pH (Fig. 1E). We also observed a decreased secretion of TNFα by pmel and OT-I T cells cultured at pH 6.6 (data not shown). Although a similar effect was observed in T cells isolated from OT-II mice, which are CD4+ T cells specific for OVA323-339, it was not as dramatic due to a high constitutive elaboration of IFN γ from these T cells (Fig. 1F). The suppression of IFN γ was posttranscriptional, as the IFN γ mRNA levels were not significantly different in activated pmel T cells incubated at pH 6.6, compared with those at pH 7.4 (Fig. 2A). This inhibition was also not mediated by changes in the pH. Mammalian cells in general, and immune cells in particular, have robust mechanisms that maintain a constant pH in their cytoplasm. The pH was not different, even after exposure to different pH values (Fig. 2B). One possibility is that the effects of acidic pH on CD8+ T-cell IFN γ secretion were mediated via one or more acid-sensing receptors (34), such as ASIC3, ASIC4, OGR1, and TDAG8, which are all expressed in pmel CD8+ T cells (Table 2). Evidence suggests that the effect is transduced via cAMP signaling (a TDAG8 target), as forskolin, a cAMP agonist, significantly attenuated IFN γ production, even at pH 7.4 (Fig. 2C). Also, the effect does not appear to be mediated via the PI3K pathway (an OGR1 target), as inhibition of PI3K failed to rescue IFN γ production at low pH and,

Figure 2.

T-cell characteristics. A, IFN γ mRNA levels are unaffected by pH. Levels of IFN γ mRNA in pmel T cells following a 48-hour stimulation at pH 7.4 and subsequent incubation at pH 7.4 or 6.6 for a subsequent 24 hours. Data were normalized to ribosomal protein 36B4 and expressed as mean ratio ± SD from three independent experiments; B, pH of activated T cells is unaffected by the incubation pH. Pmel T cells were activated as above and then incubated at pH 6.6 or 7.4 for 24 hours, after which they were loaded with SNARF-1, acetoxymethyl ester, acetate, washed, and resuspended in PBS (2,4) or high K+/nigericin (1,3) at pH 6.6 (1,2) or 7.4 (3,4) and the 580/640 fluorescence ratio subsequently determined by flow cytometry. The ratio shows that the pH values of cells in PBS at low and high pH were both approximately 7.2, and the ratios in nigericin show pH calibration points. C, forskolin inhibits T-cell function. Activated pmel T cells were cultured with DMSO or forskolin in the presence of gp100 peptide. After 24 hours, intracellular IFN γ was measured by flow cytometry. Data represent results from three separate experiments, and P values were determined using two-tailed Student t test.

Statistical analyses

As indicated, unpaired Mann–Whitney or two-sided Student t tests were used to compare between two treatment groups. All statistical evaluations of data were performed using the GraphPad Prism Software. Statistical significance was achieved at P < 0.05.

Results

To investigate the effect of pH on T-cell activation in vitro, we used CD8+ T cells isolated from pmel mice, which transgenically express a TCR specific for the melanocyte-associated peptide, gp10025-33. These T cells were cultured with gp10025-33 peptide for 48 hours at neutral pH and then further incubated with gp10025-33 peptide at acidic (6.6) or alkaline (7.4) pH for an additional 24 or 48 hours. As shown in Fig. 1A, there was no significant difference in the cell viability under acidic, compared with alkaline, conditions. However, at the same time, we observed a decrease in cell-associated IFN γ (Fig. 1B). In subsequent studies, we observed that the secretion of this cytokine was completely abolished in T cells cultured under acidic conditions (Fig. 1C). The effects of acidic pH were not due to irreversible effects on CD8+ signaling, as T cells, exposed to pH 6.6 for 24 hours and then shifted to pH 7.4 for 24 hours, regained the ability to secrete high levels of IFN γ (Fig. 1D). Identical results were observed when CD8+ T cells isolated from OT-1 mice, which transgenically express a TCR specific for the ovalbumin peptide (OVA323-339), were activated with OVA323-339 peptide at low pH (Fig. 1E). We also observed a decreased secretion of TNFα by pmel and OT-I T cells cultured at pH 6.6 (data not shown). Although a similar effect was observed in T cells isolated from OT-II mice, which are CD4+ T cells specific for OVA323-339, it was not as dramatic due to a high constitutive elaboration of IFN γ from these T cells (Fig. 1F). The suppression of IFN γ was posttranscriptional, as the IFN γ mRNA levels were not significantly different in activated pmel T cells incubated at pH 6.6, compared with those at pH 7.4 (Fig. 2A). This inhibition was also not mediated by changes in the pH. Mammalian cells in general, and immune cells in particular, have robust mechanisms that maintain a constant pH in their cytoplasm. The pH was not different, even after exposure to different pH values (Fig. 2B). One possibility is that the effects of acidic pH on CD8+ T-cell IFN γ secretion were mediated via one or more acid-sensing receptors (34), such as ASIC3, ASIC4, OGR1, and TDAG8, which are all expressed in pmel CD8+ T cells (Table 2). Evidence suggests that the effect is transduced via cAMP signaling (a TDAG8 target), as forskolin, a cAMP agonist, significantly attenuated IFN γ production, even at pH 7.4 (Fig. 2C). Also, the effect does not appear to be mediated via the PI3K pathway (an OGR1 target), as inhibition of PI3K failed to rescue IFN γ production at low pH and,
indeed, led to a general inhibition at all pHs (Supplementary Fig. S1). A known function of cAMP-activated protein kinase-A is to inhibit glycolysis. We observed that activated pmel T cells at low pH had high oxygen consumption rates and low glucose-stimulated acidification rates compared with cells cultured at high pH (Fig. 3). A similar effect was observed in OT-I T cells stimulated with OVA SIINFEKL peptide (Supplementary Fig. S2). Unstimulated T cells are not metabolically active, and there is no effect of low pH (data not shown). This reduction of glycolysis may be consistent with the observed sequestration of IFNγ mRNA in cells with low glycolytic rates (39). To investigate the acid sensor, TDAG8, in more detail, T cells were isolated from TDAG8 KO or WT mice and stimulated in the presence of anti-CD3 antibodies for 48 hours at pH 6.6 or 7.4. In both TDAG8 KO and WT T cells, IFNγ production was abolished at pH 6.6 (Supplementary Fig. S3). This suggests that TDAG8 alone is not responsible for the extracellular sensing of acidity in T cells. Investigations into this and other acid-sensing receptors are ongoing to determine whether inhibition alone or in combination is effective in rescuing the phenotype at low pH.

In vivo, the acidic pH of tumors can be increased by providing mice with 200 mmol/L ad lib sodium bicarbonate in drinking water (Fig. 4A). In numerous previous studies, this effect was shown to be specifically caused by buffering the pH of tumors, as it does not cause systemic alkalization nor is it due to the additional sodium load. These results were consistent with prior work in animal models where oral buffers that raise tumor pH were shown to inhibit spontaneous and experimental metastases (27, 40–42). In prior studies, bicarbonate has shown little to no effect on the growth rate of primary human tumor xenografts, neither in immunodeficient mice nor in fast-growing and aggressive B16 melanoma tumors in immunocompetent mice (28). However, in a transgenic (TRAMP) model of prostate cancer, bicarbonate therapy was shown to impair tumor development and subsequent metastases (41). In this study, as before, bicarbonate therapy had no effect on the growth rate of B16 tumors in immunocompetent C57BL/6 mice (Fig. 4B). However, there were significant ($P < 0.01$) effects of bicarbonate monotherapy on the growth of Yumm 1.1 melanoma (Fig. 4C and D). Notably, bicarbonate therapy led to significant increases in CD8+ T-cell infiltration into the Yumm 1.1 tumor (Fig. 4E). Bicarbonate monotherapy had no effect on T-cell infiltration into B16 tumors (data not shown), consistent with a lack of effect on primary tumor growth.

### Table 2. H+ sensors in T cells (qRT-PCR)

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Level</th>
<th>Second messenger</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASIC-1</td>
<td>+</td>
<td>[Ca2+]</td>
</tr>
<tr>
<td>ASIC-2</td>
<td>+</td>
<td>[Ca2+]</td>
</tr>
<tr>
<td>ASIC-3</td>
<td>+++</td>
<td>Na+</td>
</tr>
<tr>
<td>ASIC-4</td>
<td>+++</td>
<td>Na+</td>
</tr>
<tr>
<td>TRPV</td>
<td>–</td>
<td>cAMP</td>
</tr>
<tr>
<td>GPR4</td>
<td>+++</td>
<td>cAMP</td>
</tr>
<tr>
<td>TDAG8</td>
<td>+++</td>
<td>cAMP</td>
</tr>
<tr>
<td>OGR1</td>
<td>+++</td>
<td>PI3K</td>
</tr>
</tbody>
</table>

Figure 3. pmel T-cell metabolism. Pmel T cells were activated with gp10025-33 peptide for 48 hours, followed by a subsequent 48-hour incubation at either pH 6.7 or 7.4. Cells were subsequently metabolically profiled using a Seahorse XF-96 Analyzer. A, representative results of a glucose stress test, which measures extracellular acidification rate (ECAR) following addition of glucose (Gluc.), oligomycin (Oligo), and 2-deoxy glucose (2-DG). B, representative results of a mitochondrial stress test, which measures the oxygen consumption rate (OCR) in glucose-containing media, following sequential additions of oligomycin, FCCP, and rotenone/antimycin A. See Materials and Methods for description of glucose stress test and mitochondrial stress test. C, acidosis inhibits T-cell glycolysis. Data show the glucose-stimulated increase in ECAR. D, acidic cells are more oxidative. Data show the basal OCR for activated cells incubated at pH 6.7 or 7.4. Data represent results from three separate experiments, with six replicates per experiment. A two-tailed Student t test was used to calculate statistical significance.
B7 and PD-L1/L2 ligands are ligands expressed by antigen-presenting cells that inhibit T-cell activation by binding to cognate checkpoint receptors CTLA4 and PD1, respectively, (43, 44), that are expressed on CD8+ cytotoxic T cells. Neutralizing antibodies against CTLA4 and PD1 are being used clinically to prolong antitumor T-cell responses, and, in trials to date, response rates in melanoma range from 18% to 35% (6, 7). Given the inhibitory effect of acidosis on T cells and the systemic effects of bicarbonate, we therefore assessed if bicarbonate would augment antitumor responses in combination with anti-CTLA4 or anti-PD1 antibody therapy. We hypothesized that bicarbonate would augment antitumor responses in combination with anti-CTLA4 or anti-PD1 antibody therapy. We observed that combinations of bicarbonate therapy with anti-CTLA4 (Fig. 5A and B) or anti-PD1 (Fig. 5C and D) antibodies significantly improved the antitumor effects of these therapies in the B16 melanoma model that was resistant to bicarbonate alone. Although the effects on tumor growth appear modest, the morphologies of the tumors were dramatically affected by bicarbonate, in that they were macroscopically more vascularized, compared with controls (Supplementary Fig. S4). This was not a systemic effect, as there were no differences in splenic T-cell responses induced by bicarbonate in combination with PD-1 (Supplementary Fig. S4). In patients, anti-PD1 and anti-CTLA4 antibody therapies are being increasingly used in combination. When these agents were combined, there were only modest effects of adding bicarbonate therapy (Fig. 5E), likely because the combination of these checkpoint inhibitors was by itself so effective. Notably, bicarbonate in combination with either checkpoint inhibitor was as effective in suppressing tumor growth as the two-checkpoint inhibitor combination (compare Fig. 5E with 5A or 5C). Notably, the combination of bicarbonate with PD-1 checkpoint blockade was also effective in a Panc02 pancreatic cancer model. In this system, treatment with bicarbonate or anti-PD1 antibody alone had no effect on tumor growth, whereas tumors treated with combination were significantly smaller (Fig. 5F).

Anticancer immunotherapy also includes the adoptive cell transfer (ACT) of tumor-specific T cells. In ACT, syngeneic recipient mice bearing B16 melanomas were treated with 600 rad to deplete peripheral blood mononuclear cells, and 1 day later were infused with 10 million activated pmel (Thy1.1) T cells and subsequently treated twice a day with 250,000 IU of IL2 for 3 days. As expected, adoptive transfer alone caused significant reductions in the tumor growth rates, yet an improved antitumor response was evident, albeit not significantly, in combination with bicarbonate (Fig. 6A). However, long-term follow up showed that the combination of bicarbonate + ACT led to a long-term (censored at 120 day) survival rate of 40%, compared with 10% for ACT with pmel T cells alone (Fig. 6B). Importantly, the beneficial effects of bicarbonate were associated with
significant increases in T-cell persistence (Fig. 6C), a sensitive biomarker for response to adoptive T-cell therapy (45).

Discussion

In this study, we have shown that the acidic pH encountered in a tumor microenvironment has significant immunosuppressive effects. In vitro, acidic pH was shown to profoundly inhibit T-cell responses, including an abrogation of IFNγ and TNFα secretion, suggesting that an acidic environment may lead to a general block of translation of proinflammatory cytokines. This does not appear to be a general blockade of exocytosis, as the intracellular levels of IFNγ protein were likewise reduced and, indeed, low pH has been shown to stimulate exocytosis in a number of systems (46). An inhibition of glycolytic activation, which is necessary for T-cell activation, was also observed. Additional studies will be required to define the molecular mechanisms leading to the inhibition of glycolytic activation by acidic pH in this system. This is a significant scientific problem as acid-induced inhibition of glycolysis is known to occur in almost all systems, yet the signal transduction events are unknown. In vivo, treatment of mice bearing melanoma with bicarbonate therapy raised tumor pH and increased the durable response rates to both checkpoint inhibition (PD-1 and CTLA4) and adoptive cell therapy. In prior work, we have shown that buffer therapy induces "compensated metabolic alkalosis" and works by buffering the tumor pH to more neutral values, without affecting systemic pH (47).

We have calculated from these mouse studies that the human equivalent dose would be bicarbonate at 800 mg kg⁻¹ d⁻¹. This dose is clinically achievable, and early-phase I clinical trials of bicarbonate therapy have been conducted. Buffer therapy directly targets the tumor pH, but there are alternative pharmacologic approaches that may indirectly lead to the same effect, i.e., compensated metabolic alkalosis, such as K-sparing diuretics (acetazolamide) or pan-specific carbonic anhydrase inhibitors (acetazolamide). Other approaches could target the rate of tumor acid production through either isomorph-specific CAIX inhibitors (DH-348) or inhibition of LDH-A (FX-11). The ability of these agents to neutralize tumor pH is not known, nor are their effects on antitumor immunotherapy.

Harold Dvorak famously characterized tumors as “wounds that do not heal” (48). One component of the wound response is a transient ischemia–driven tissue acidification, which resolves as the wound heals (49). The role of acidification in physiologic wound healing is not known with certainty, but recent data suggest that acidification stimulates the production...
of inflammatory cytokines by the stroma or endothelium (50). As these induce neoangiogenesis, the acidosis is reduced and inflammation resolves. Our data and work cited herein would suggest that, while acidification may send an inflammatory signal, T cells are unable to activate until the pH becomes more alkaline. In tumors, this acidification never resolves, and artificially raising the pH of tumors through buffer therapy allows the "wound" to heal by promoting antitumor immunity.

Disclosure of Potential Conflicts of Interest
R.J. Gillies has ownership interest (including patents) in and is a consultant/advisory board member for HealthMyne, Inc. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: S. Pilon-Thomas, A.E. El-Kenawi, K. Luddy, M. Damaghi, J.J. Mulé, A. Ibrahim-Hashim, R.J. Gillies
Development of methodology: S. Pilon-Thomas, K.N. Kodumudi, A.E. El-Kenawi, K. Luddy, A. Ibrahim-Hashim, R.J. Gillies
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Pilon-Thomas, A.E. El-Kenawi, S. Russell, M. Damaghi, J.W. Wojtkowiak, A. Ibrahim-Hashim, R.J. Gillies
Writing, review, and/or revision of the manuscript: S. Pilon-Thomas, K.N. Kodumudi, A.E. El-Kenawi, M. Damaghi, J.J. Mulé, A. Ibrahim-Hashim, R.J. Gillies
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Pilon-Thomas, A.M. Weber, A. Ibrahim-Hashim, R.J. Gillies
Study supervision: S. Pilon-Thomas, K.N. Kodumudi, A. Ibrahim-Hashim, R.J. Gillies

Acknowledgments
The authors thank Ms. Ellen Moore for technical assistance and Dr. Estaban Celis for early discussions of this approach.

Grant Support
This work was supported by USPHS grant R01CA077575 (R.J. Gillies), P50CA168536 (S. Pilon-Thomas), and Moffitt Cancer Center Support Grant P50CA076292.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 30, 2015; revised November 24, 2015; accepted December 9, 2015; published OnlineFirst December 30, 2015.
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy

Shari Pilon-Thomas, Krithika N. Kodumudi, Asmaa E. El-Kenawi, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-15-1743

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2015/12/30/0008-5472.CAN-15-1743.DC1

Cited articles
This article cites 48 articles, 13 of which you can access for free at:
http://cancerres.aacrjournals.org/content/76/6/1381.full.html#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
/content/76/6/1381.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.